Drug · DIN 02490064
ESPEROCT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 10, 2022; first marketed March 10, 2022.
- Drug Identification Number (DIN)
- 02490064
- Company (DIN owner)
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Coagulation factor viii B02BD02
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED | 500 UNIT | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 4, 2019: NOC 22386New Drug Submission (NDS)
Other DINs named ESPEROCT
- DIN 02490072 · Marketed
- DIN 02490099 · Marketed
- DIN 02490102 · Marketed
- DIN 02490080 · Approved